(2R,3R,4S,5S,6R)-4-Amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-YL]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3R,4S,5S,6R)-4-Amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-YL]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
• 英文别名: 4-amino-2-[4,6-diamino-3-[3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
• 化学式: C₁₈H₃₇N₅O₈
• 分子量: 451.5
• InChiKey: JJCQSGDBDPYCEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.8
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  248
• 氢给体数：
  9
• 氢受体数：
  13

反应信息

• 作为反应物：
  描述：

  (2R,3R,4S,5S,6R)-4-Amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-YL]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol 生成 benzyl N-[(2R,3R,6S)-2-[(1R,2S,3S,4R,6S)-4-amino-3-[(2S,3R,4S,5S,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-2-hydroxy-6-(phenylmethoxycarbonylamino)cyclohexyl]oxy-6-(phenylmethoxycarbonylaminomethyl)oxan-3-yl]carbamate
  参考文献：
  名称：

  MATSUDA, KEIJI;YASUDA, NOBUYOSHI;TSUTSUMI, HIDEO;TAKAYA, TAKAO, J. ANTIBIOTICS, 40,(1987) N 6, 843-854

  摘要：

  DOI：

文献信息

• ARBEKACIN DERIVATIVE, AND PRODUCTION AND USE THEREOF
  申请人：MEIJI SEIKA PHARMA CO., LTD.

  公开号：US20160096859A1

  公开（公告）日：2016-04-07

  It has been found that adding carbon dioxide or the like to a solution containing arbekacin free base makes it possible to produce arbekacin derivatives including arbekacin carbonate and carbamic acid of arbekacin. Moreover, it has been found that the arbekacin derivatives have a high stability, and that the use thereof enables efficient productions of highly-pure arbekacin free base and pharmaceutically acceptable salt thereof.

  已经发现将二氧化碳或类似物质添加到含有阿贝卡星游离基的溶液中，可以生产包括阿贝卡星碳酸盐和阿贝卡星的氨基甲酸酯在内的阿贝卡星衍生物。此外，已经发现阿贝卡星衍生物具有高稳定性，并且使用它们可以有效地生产高纯度的阿贝卡星游离基和其药用可接受盐。
• Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto
  申请人：THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

  公开号：US11421044B2

  公开（公告）日：2022-08-23

  Several embodiments of NO releasing structures are disclosed. In some embodiments, the structures are covalently modified to store and release nitric oxide. Some embodiments pertain to methods of making and use of these structures. The covalently modified polymer structures may be tailored to release nitric oxide in a controlled manner and are useful for treatment of various medical conditions.

  本文公开了几种一氧化氮释放结构的实施方案。在某些实施方案中，这些结构经过共价修饰，可储存和释放一氧化氮。一些实施方案涉及这些结构的制造和使用方法。共价修饰的聚合物结构可定制为以受控方式释放一氧化氮，可用于治疗各种病症。
• Aminoglycoside antibiotics for use as vap-1/ssao inhibitors
  申请人：Jalkanen Sirpa

  公开号：US20070093433A1

  公开（公告）日：2007-04-26

  The present invention concerns the use of a compound comprising one or more sugar moieties, which optionally are aminosubstitutes, and possibly other moieties, wherein said compound is a molecule comprising at least two aminosubstituents, said aminosubstituents being primary, secondary or tertiary amino groups, wherein said aminosubstituents are either attached to one single sugar moiety or attached to several sugar moieties or other moieties of the molecule, or to chains connecting two moieties or to chains being substituents to the molecule, for the manufacture of a pharmaceutical preparation useful as an agent capable of influencing an amine oxidase enzyme activity, more particularly inhibiting VAP-1/SSAO activity. The preferred compounds are aminoglycoside antibiotics, e.g., streptomycin, netilmicin, geneticin, gentamicin, puromycin, tobramycin and amikacin. The preferred conditions to be treated are inflammatory diseases or conditions, diseases related to carbohydrate metabolism, diseases related to aberrations in adipocyte differentiation or function or smooth muscle cell function, and vascular diseases.
• Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
  申请人：Ellis James L.

  公开号：US20090042819A1

  公开（公告）日：2009-02-12

  The invention describes novel organic nitric oxide donor salts of a antimicrobial compounds, and novel compositions and kits comprising at least one organic nitric oxide donor salt of an antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. In one embodiment the antimicrobial compounds of the invention are aztreonam, ciprofloxacin, doripenam, duramycin and tobramycin. The organic nitric oxide donors that form salts are preferably organic nitrates, organic nitrites, nitrosothiols, thionitrites and heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. The methods of the invention are preferably for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating Bacillus anthracis infections.
• US20140274932A1
  申请人：——

  公开号：US20140274932A1

  公开（公告）日：2014-09-18